SCHEMBL4067663

SCHEMBL4067663

[CH](CNCc1ccccn1)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.50
MAOA P21397 2/20 0.49
MAOB P27338 2/20 0.49
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 3/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SIRT2 Q8IXJ6 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CCR5 P51681 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2947235 0.79 ALDH1A1 (0.63) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL4065565 0.79 MEN1 (0.54) CHRM2MAOAMAOBMEN1KMT2A
SCHEMBL12832037 0.78 CHRM2 (0.58) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL4068013 0.77 SLC2A4 (0.46) ALDH1A1MEN1KMT2ATDP1SMN1; SMN2
SCHEMBL29438821 0.76 CHRM2 (0.70) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL230222 0.76 CHRM2 (0.70) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL5411231 0.76 CHRM2 (0.56) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL29761156 0.76 CHRM2 (0.66) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL1632589 0.76 CHRM2 (0.56) CHRM2MAOAMAOBALDH1A1MEN1
SCHEMBL25211342 0.74 CHRM2 (0.68) CHRM2MAOAMAOBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1415986-B1 SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS BANYU PHARMA CO LTD (JP) 2009-04-08 EP disclosed
US-7205417-B2 Spiro compounds BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-04-17 US disclosed
US-20040259890-A1 Spiro compounds MSD K.K. (JP) 2004-12-23 US disclosed
CN-1538956-A Spiro compounds ������ҩ��ʽ���� 2004-10-20 CN disclosed
EP-1415986-A1 SPIRO COMPOUNDS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259890-A1 Spiro compounds OPRD1, PER2, OPRK1 CHRM2 128/4885MAOA 714/4885MAOB 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.